News

EurekAlert!2mon

Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: Another weapon in the armamentarium

The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...
Morningstar4mon

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Healio2y

Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer

Please provide your email address to receive an email when new articles are posted on . Patients who received torpialimab in addition to nab-paclitaxel had longer median PFS (8.4 months vs. 5.6 months ...
Nasdaq3y

Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180 ...
MedPage Today1y

FDA OKs First Drug for Nasopharyngeal Carcinoma

The FDA approved a new PD-1 inhibitor, toripalimab (Loqtorzi), for treating adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), representing the first drug specifically approved for ...
The Bakersfield Californian1mon

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line ...

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Morningstar5mon

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Renal & Urology News1y

Toripalimab Plus Axitinib May Be New Standard First-Line Treatment for Advanced RCC

Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...
Nasdaq9mon

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced ...
PE Hub1y

SK Capital’s Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences. No financial terms of ...